CoChat

Activation of DR3 signaling causes loss of ILC3s and exacerbates intestinal inflammation

Open access
Li, Jingyu, Shi, Wenli, Sun, Hanxiao, Ji, Yan, Chen, Yuqin, Guo, Xiaohuan, Sheng, Huiming, Shu, Jie, Zhou, Liang, Cai, Ting, Qiu, Ju · 2019 · Nature Communications
Cited by 63

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

TNF-like ligand 1 A (TL1A) and death receptor 3 (DR3) are a ligand-receptor pair involved in the pathogenesis of inflammatory bowel disease. Group 3 innate lymphoid cells (ILC3s) regulate intestinal immunity and highly express DR3. Here, we report that activation of DR3 signaling by an agonistic anti-DR3 antibody increases GM-CSF production from ILC3s through the p38 MAPK pathway. GM-CSF causes accumulation of eosinophils, neutrophils and CD11b+CD11c+ myeloid cells, resulting in loss of ILC3s from the intestine in an IL-23-dependent manner and exacerbating colitis. Blockade of GM-CSF or IL-23 reverses anti-DR3 antibody-driven ILC3 loss, whereas overexpression of IL-23 induces loss of ILC3s in the absence of GM-CSF. Neutralization of TL1A by soluble DR3 ameliorates both DSS and anti-CD40 antibody-induced colitis. Moreover, ILC3s are required for the deleterious effect of anti-DR3 antibodies on innate colitis. These findings clarify the process and consequences of DR3 signaling-induced intestinal inflammation through regulation of ILC3s.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-11304-8

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 59

  1. Meylan, F., Richard, A. C. & Siegel, R. M. TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol. Rev. 244, 188–196 (2011). · DOI · Paper page
  2. Meylan, F. et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 29, 79–89 (2008). · DOI · Paper page
  3. Meylan, F. et al. The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells. Mucosal Immunol. 7, 958–968 (2014). · DOI · Paper page
  4. Aiba, Y. & Nakamura, M. The role of TL1A and DR3 in autoimmune and inflammatory diseases. Mediat. Inflamm. 2013, 258164 (2013). · DOI
  5. Pappu, B. P. et al. TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J. Exp. Med. 205, 1049–1062 (2008). · DOI · Paper page
  6. Schreiber, T. H. et al. Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. J. Clin. Investig. 120, 3629–3640 (2010). · DOI · Paper page
  7. Khan, S. Q. et al. Cloning, expression, and functional characterization of TL1A-Ig. J. Immunol. 190, 1540–1550 (2013). · DOI
  8. Nishikii, H. et al. DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease. Blood 128, 2846–2858 (2016). · DOI
  9. Kim, B. S. et al. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease. Blood 126, 546–557 (2015). · DOI
  10. Madireddi, S. et al. Regulatory T cell-mediated suppression of inflammation induced by DR3 signaling is dependent on galectin-9. J. Immunol. 199, 2721–2728 (2017). · DOI
  11. Jia, L. G. et al. A novel role for TL1A/DR3 in Protection against intestinal injury and infection. J. Immunol. 197, 377–386 (2016). · DOI
  12. Bamias, G., Jia, L. G. & Cominelli, F. The tumor necrosis factor-like cytokine 1A/death receptor 3 cytokine system in intestinal inflammation. Curr. Opin. Gastroenterol. 29, 597–602 (2013). · DOI
  13. Li, Z. et al. Death receptor 3 signaling controls the balance between regulatory and effector lymphocytes in SAMP1/YitFc mice with Crohn’s disease-like ileitis. Front. Immunol. 9, 362 (2018). · DOI
  14. Butto, L. F. et al. Death-domain-receptor 3 deletion normalizes inflammatory gene expression and prevents ileitis in experimental Crohn’s disease. Inflamm. Bowel Dis. 25, 14–26 (2019). · DOI
  15. Yamazaki, K. et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn’s disease. Hum. Mol. Genet. 14, 3499–3506 (2005). · DOI · Paper page
  16. Siakavellas, S. I. & Bamias, G. Tumor necrosis factor-like cytokine TL1A and its receptors DR3 and DcR3: important new factors in mucosal homeostasis and inflammation. Inflamm. Bowel Dis. 21, 2441–2452 (2015).
  17. Yu, X. et al. TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers. Mucosal Immunol. 7, 730–740 (2014). · DOI · Paper page
  18. Takedatsu, H. et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 135, 552–567 (2008). · DOI · Paper page
  19. Lanier, L. L. Shades of grey–the blurring view of innate and adaptive immunity. Nat. Rev. Immunol. 13, 73–74 (2013). · DOI
  20. Kim BS, Artis D. Group 2 innate lymphoid cells in health and disease. Cold Spring Harb. Perspect. Biol. 7, a016337 (2015). · DOI · Paper page
  21. Geremia, A. & Arancibia-Carcamo, C. V. Innate lymphoid cells in intestinal inflammation. Front Immunol. 8, 1296 (2017). · DOI · Paper page
  22. Longman, R. S. et al. CX(3)CR1(+) mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. J. Exp. Med. 211, 1571–1583 (2014). · DOI · Paper page
  23. Griseri, T. et al. Granulocyte macrophage colony-stimulating factor-activated eosinophils promote interleukin-23 driven chronic colitis. Immunity 43, 187–199 (2015). · DOI · Paper page
  24. Pearson, C. et al. ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation. eLife 5, e10066 (2016). · DOI · Paper page
  25. Bernink, J. H. et al. Interleukin-12 and -23 control plasticity of CD127(+) group 1 and group 3 innate lymphoid cells in the intestinal lamina propria. Immunity 43, 146–160 (2015). · DOI · Paper page
  26. Takayama, T. et al. Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn’s disease. Gastroenterology 139, 882–892 (2010). 892 e881-883. · DOI · Paper page
  27. Spits, H. et al. Innate lymphoid cells–a proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145–149 (2013). · DOI · Paper page
  28. Qiu, J. et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 36, 92–104 (2012). · DOI · Paper page
  29. Sonnenberg, G. F., Monticelli, L. A., Elloso, M. M., Fouser, L. A. & Artis, D. CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 34, 122–134 (2011). · DOI · Paper page
  30. Eberl, G. et al. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat. Immunol. 5, 64–73 (2004). · DOI · Paper page
  31. Gerdes, J. et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am. J. Pathol. 138, 867–873 (1991).
  32. Migone, T. S. et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16, 479–492 (2002). · DOI · Paper page
  33. Budihardjo, I., Oliver, H., Lutter, M., Luo, X. & Wang, X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15, 269–290 (1999). · DOI · Paper page
  34. Vonarbourg, C. et al. Regulated expression of nuclear receptor RORgammat confers distinct functional fates to NK cell receptor-expressing RORgammat(+) innate lymphocytes. Immunity 33, 736–751 (2010). · DOI · Paper page
  35. Klose, C. S. N. et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 157, 340–356 (2014). · DOI · Paper page
  36. Srinivas, S. et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 1, 4 (2001). · DOI · Paper page
  37. Walker, J. A. & McKenzie, A. N. Development and function of group 2 innate lymphoid cells. Curr. Opin. Immunol. 25, 148–155 (2013). · DOI · Paper page
  38. Becher, B., Tugues, S. & Greter, M. GM-CSF: from growth factor to central mediator of tissue inflammation. Immunity 45, 963–973 (2016). · DOI · Paper page
  39. Satoh-Takayama, N. et al. The chemokine receptor CXCR6 controls the functional topography of interleukin-22 producing intestinal innate lymphoid cells. Immunity 41, 776–788 (2014). · DOI
  40. Macho-Fernandez, E. et al. Lymphotoxin beta receptor signaling limits mucosal damage through driving IL-23 production by epithelial cells. Mucosal Immunol. 8, 403–413 (2015). · DOI · Paper page
  41. Kim, M. Y. et al. Neonatal and adult CD4+ CD3- cells share similar gene expression profile, and neonatal cells up-regulate OX40 ligand in response to TL1A (TNFSF15). J. Immunol. 177, 3074–3081 (2006). · DOI
  42. Wang, Y. et al. Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection. Immunity 32, 403–413 (2010). · DOI · Paper page
  43. Eken, A., Singh, A. K., Treuting, P. M. & Oukka, M. IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism. Mucosal Immunol. 7, 143–154 (2014). · DOI · Paper page
  44. Ridley, A. J. Rho GTPase signalling in cell migration. Curr. Opin. Cell Biol. 36, 103–112 (2015). · DOI · Paper page
  45. Kim, M. H., Taparowsky, E. J. & Kim, C. H. Retinoic acid differentially regulates the migration of innate lymphoid cell subsets to the gut. Immunity 43, 107–119 (2015). · DOI · Paper page
  46. Hepworth, M. R. et al. Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature 498, 113–117 (2013). · DOI · Paper page
  47. Hepworth, M. R. et al. Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4(+) T cells. Science 348, 1031–1035 (2015). · DOI · Paper page
  48. Tiedje, C. et al. The RNA-binding protein TTP is a global post-transcriptional regulator of feedback control in inflammation. Nucleic Acids Res. 44, 7418–7440 (2016).
  49. Pobezinskaya, Y. L., Choksi, S., Morgan, M. J., Cao, X. & Liu, Z. G. The adaptor protein TRADD is essential for TNF-like ligand 1A/death receptor 3 signaling. J. Immunol. 186, 5212–5216 (2011). · DOI · Paper page
  50. Slebioda, T. J. et al. Triggering of TNFRSF25 promotes CD8(+) T-cell responses and anti-tumor immunity. Eur. J. Immunol. 41, 2606–2611 (2011). · DOI
  51. Castellanos, J. G. et al. Microbiota-induced TNF-like ligand 1A drives group 3 innate lymphoid cell-mediated barrier protection and intestinal T cell activation during colitis. Immunity 49, 1077–1089 e1075 (2018). · DOI · Paper page
  52. Chen, L. et al. IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology. Mucosal Immunol. 8, 390–402 (2015). · DOI
  53. Paustian, A. M. S. et al. Continuous IL-23 stimulation drives ILC3 depletion in the upper GI tract and, in combination with TNFalpha, induces robust activation and a phenotypic switch of ILC3. PLoS ONE 12, e0182841 (2017). · DOI
  54. Kearney, C. J. & Martin, S. J. An inflammatory perspective on necroptosis. Mol. Cell 65, 965–973 (2017). · DOI · Paper page
  55. Tomura, M. et al. Monitoring cellular movement in vivo with photoconvertible fluorescence protein “Kaede” transgenic mice. Proc. Natl Acad. Sci. USA 105, 10871–10876 (2008). · DOI · Paper page
  56. Mackley, E. C. et al. CCR7-dependent trafficking of RORgamma(+) ILCs creates a unique microenvironment within mucosal draining lymph nodes. Nat. Commun. 6, 5862 (2015). · DOI · Paper page
  57. Uhlig, H. H. et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25, 309–318 (2006). · DOI · Paper page
  58. Lieschke, G. J., Rao, P. K., Gately, M. K. & Mulligan, R. C. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat. Biotechnol. 15, 35–40 (1997). · DOI
  59. Pavlick, K. P. et al. Role of T-cell-associated lymphocyte function-associated antigen-1 in the pathogenesis of experimental colitis. Int Immunol. 18, 389–398 (2006). · doi:10.1093/intimm/dxh378

Cited by

See all 63

Metadata

Authors
Li, J., Shi, W., Sun, H., Ji, Y., Chen, Y., Guo, X., Sheng, H., Shu, J., Zhou, L., Cai, T., & Qiu, J.
Venue
Nature Communications
Published
2019-07-29
Volume
10
Issue
1
Pages
3371-3371
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2965829044
Cited by
63
References
7
FWCI
2.16
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activation of DR3 signaling causes loss of ILC3s and exacerbates intestinal inflammation. https://app.cochat.ai/papers/10.1038/s41467-019-11304-8
The paper
Li, J., Shi, W., Sun, H., Ji, Y., Chen, Y., Guo, X., Sheng, H., Shu, J., Zhou, L., Cai, T., & Qiu, J. (2019). Activation of DR3 signaling causes loss of ILC3s and exacerbates intestinal inflammation. Nature Communications. https://doi.org/10.1038/s41467-019-11304-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.